We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-6.36%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.58B
AUM Growth
-$367M
Cap. Flow
-$23.4M
Cap. Flow %
-1.48%
Top 10 Hldgs %
42.1%
Holding
79
New
5
Increased
1
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$14.7M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$7.59M
3
ASND icon
Ascendis Pharma A/S
ASND
+$6.6M
4
ETNB
89bio
ETNB
+$4.23M
5
COGT icon
Cogent Biosciences
COGT
+$2.9M

Top Sells

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$24.6M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$14.5M
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$5.55M
5
GNCA
Genocea Biosciences, Inc.
GNCA
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Financials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$134M 8.5%
2,000,000
– –
CYTK icon
2
Cytokinetics
CYTK
$10.5B
$82.5M 5.23%
2,100,000
– –
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$80.9M 5.13%
500,000
– –
RVMD icon
4
Revolution Medicines
RVMD
$39.9B
$67.9M 4.3%
3,484,264
– –
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$59M 3.73%
1,303,700
– –
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$51.1M 3.24%
2,075,905
– –
PMVP icon
7
PMV Pharmaceuticals
PMVP
$59.2M
$49.9M 3.16%
3,498,636
– –
RXDX
8
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$48.4M 3.06%
1,714,000
– –
TYRA icon
9
Tyra Biosciences
TYRA
$1.9B
$46.1M 2.92%
6,448,359
– –
RLAY icon
10
Relay Therapeutics
RLAY
$4.1B
$44.7M 2.83%
2,669,132
– –
ITOS
11
DELISTED
iTeos Therapeutics
ITOS
$44.4M 2.81%
2,154,058
-1,038,000
-33% -$24.6M
MRUS
12
DELISTED
Merus
MRUS
$43M 2.72%
1,900,000
– –
TPTX
13
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$42.9M 2.72%
570,745
+170,745
+43% +$7.59M
AMLX icon
14
Amylyx Pharmaceuticals
AMLX
$2.26B
$42.4M 2.68%
2,200,000
– –
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$37.7M 2.38%
1,239,000
– –
XBI icon
16
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$37.1M 2.35%
500,000
-200,000
-29% -$15M
RCUS icon
17
Arcus Biosciences
RCUS
$3.55B
$36.3M 2.3%
1,432,200
– –
SAGE
18
DELISTED
Sage Therapeutics
SAGE
$35.3M 2.24%
1,094,000
– –
TNGX icon
19
Tango Therapeutics
TNGX
$4.43B
$31.1M 1.97%
6,871,642
– –
IDYA icon
20
IDEAYA Biosciences
IDYA
$3.42B
$30.4M 1.93%
2,202,812
– –
BLU
21
DELISTED
BELLUS Health Inc.
BLU
$29.6M 1.87%
3,200,000
– –
ANAB icon
22
AnaptysBio
ANAB
$1.58B
$26.4M 1.67%
1,300,000
– –
BPMC
23
DELISTED
Blueprint Medicines
BPMC
$25.6M 1.62%
507,374
– –
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$25M 1.58%
2,325,000
– –
KNTE
25
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$23.3M 1.48%
1,847,559
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Boxer Capital held 79 positions worth $1.58B, down 19% from $1.95B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Boxer Capital's Q2 2022 filing shows 5 new, 1 increased, 2 reduced and 3 closed positions. Its largest new stake was Sarepta Therapeutics: 200,000 shares worth $15M. The largest sale was iTeos Therapeutics, an estimated $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q2 2022 buy was Sarepta Therapeutics: 200,000 shares worth $15M.
  • Boxer Capital added most to Turning Point Therapeutics, Inc. Common Stock in Q2 2022, an estimated $7.59M increase.
  • Boxer Capital's biggest Q2 2022 reduction was iTeos Therapeutics, cutting an estimated $24.6M.
  • Boxer Capital fully exited Ultragenyx Pharmaceutical in Q2 2022, selling an estimated $14.5M.
  • Boxer Capital's ten largest holdings make up 42% of its $1.58B portfolio in Q2 2022.
  • Boxer Capital opened 5 new positions and closed 3 in Q2 2022.
  • Boxer Capital's portfolio value fell 19% quarter-over-quarter to $1.58B.

Based on Boxer Capital's 13F filing for Q2 2022, filed 15 Aug 2022.